<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198715</url>
  </required_header>
  <id_info>
    <org_study_id>DS1040-A-J110</org_study_id>
    <secondary_id>173612</secondary_id>
    <nct_id>NCT03198715</nct_id>
  </id_info>
  <brief_title>Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy</brief_title>
  <official_title>A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic
      stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by
      intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is
      determined that each dose is safe and tolerable, the next higher dose will be given to the
      next group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2017</start_date>
  <completion_date type="Actual">January 19, 2020</completion_date>
  <primary_completion_date type="Actual">January 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with intracranial hemorrhage (ICH), with or without symptoms, within 36 hours from start of treatment</measure>
    <time_frame>within 36 hours from start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with non-ICH major bleeding within 96 hours from start of treatment</measure>
    <time_frame>within 96 hours from start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of DS-1040a in plasma</measure>
    <time_frame>within 96 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of DS-1040a in plasma</measure>
    <time_frame>within 96 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) of DS-1040a in plasma</measure>
    <time_frame>within 96 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (T1/2) of DS-1040a in plasma</measure>
    <time_frame>within 96 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug excreted in urine of DS-1040a</measure>
    <time_frame>within 24 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin activatable fibrinolysis inhibitor (TAFI) antigen in plasma</measure>
    <time_frame>within 48 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer in plasma</measure>
    <time_frame>within 48 hours from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total TAFIa inhibitor in plasma</measure>
    <time_frame>within 48 hours from start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>DS-1040b 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-1040b 1.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-1040b 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-1040b 4.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive saline by intravenous infusion over six hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS1040b</intervention_name>
    <description>DS-1040b in solution for intravenous infusion</description>
    <arm_group_label>DS-1040b 0.6 mg</arm_group_label>
    <arm_group_label>DS-1040b 1.2 mg</arm_group_label>
    <arm_group_label>DS-1040b 2.4 mg</arm_group_label>
    <arm_group_label>DS-1040b 4.8 mg</arm_group_label>
    <other_name>Investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution for intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is an acute ischemic stroke patients with evidence of intracranial vascular occlusion

          -  Is enrolled in principle within 8 hours of symptom onset

          -  Has treatment plan that includes stent retriever

          -  Has protocol-defined scores on several scales

        Exclusion Criteria:

          -  Has treatment plan that includes fibrinolysis or fibinolysis

          -  Has identified intracranial hemorrhage or subarachnoid hemorrhage

          -  Has active bleeding like gastrointestinal hemorrhage

          -  Has cerebral bleeding risk; intracranial tumor, brain aneurysm, cerebral arteriovenous
             malformation, or history of intracranial bleeding

          -  Has severe hepatic or renal impairment

          -  Has been a participant in other clinical trial within 30 days prior to treatment

          -  Is pregnant, lactating, or planning on becoming pregnant during treatment period

          -  Has any condition or history that might, per protocol or in the opinion of the
             investigator, compromise:

               1. safety or well-being of the participant or their offspring

               2. safety of the study staff

               3. analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Funabashi Municipal Medical Center</name>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <zip>273-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuota</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mihara Memorial Hospital</name>
      <address>
        <city>Isesaki</city>
        <state>Gunma</state>
        <zip>372-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Organization of Occupational Health and Safety Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine College Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Prefectural Central Hospital</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seisho Hospital</name>
      <address>
        <city>Odawara</city>
        <state>Kanagawa</state>
        <zip>250-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata City General Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-1197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrinolysis enhancer</keyword>
  <keyword>TAFIa inhibitor</keyword>
  <keyword>Developmental Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

